Propagation of Population Pharmacokinetic Information Using a Bayesian Approach: Comparison with Meta-Analysis

We investigated the propagation of population pharmacokinetic information across clinical studies by applying Bayesian techniques. The aim was to summarize the population pharmacokinetic estimates of a study in appropriate statistical distributions in order to use them as Bayesian priors in consequent population pharmacokinetic analyses. Various data sets of simulated and real clinical data were fitted with WinBUGS, with and without informative priors. The posterior estimates of fittings with non-informative priors were used to build parametric informative priors and the whole procedure was carried on in a consecutive manner. The posterior distributions of the fittings with informative priors where compared to those of the meta-analysis fittings of the respective combinations of data sets. Good agreement was found, for the simulated and experimental datasets when the populations were exchangeable, with the posterior distribution from the fittings with the prior to be nearly identical to the ones estimated with meta-analysis. However, when populations were not exchangeble an alternative parametric form for the prior, the natural conjugate prior, had to be used in order to have consistent results.In conclusion, the results of a population pharmacokinetic analysis may be summarized in Bayesian prior distributions that can be used consecutively with other analyses. The procedure is an alternative to meta-analysis and gives comparable results. It has the advantage that it is faster than the meta-analysis, due to the large datasets used with the latter and can be performed when the data included in the prior are not actually available.

[1]  J. Wakefield The Bayesian Analysis of Population Pharmacokinetic Models , 1996 .

[2]  Jon Wakefield,et al.  Bayesian Analysis of Population PK/PD Models: General Concepts and Software , 2002, Journal of Pharmacokinetics and Pharmacodynamics.

[3]  J Wakefield,et al.  The Combination of Population Pharmacokinetic Studies , 2000, Biometrics.

[4]  H Putter,et al.  A Bayesian approach to parameter estimation in HIV dynamical models , 2002, Statistics in medicine.

[5]  A Racine-Poon,et al.  A Bayesian approach to nonlinear random effects models. , 1985, Biometrics.

[6]  M. Danhof,et al.  In vivo characterization of the pharmacodynamic interaction of a benzodiazepine agonist and antagonist: midazolam and flumazenil. , 1992, The Journal of pharmacology and experimental therapeutics.

[7]  Gordon Graham,et al.  Determination of an Optimal Dosage Regimen Using a Bayesian Decision Analysis of Efficacy and Adverse Effect Data , 2002, Journal of Pharmacokinetics and Pharmacodynamics.

[8]  R. Muirhead Aspects of Multivariate Statistical Theory , 1982, Wiley Series in Probability and Statistics.

[9]  A. Gelman,et al.  Physiological Pharmacokinetic Analysis Using Population Modeling and Informative Prior Distributions , 1996 .

[10]  Leon Aarons,et al.  A population analysis of the pharmacokinetics and pharmacodynamics of midazolam in the rat , 1991, Journal of Pharmacokinetics and Biopharmaceutics.

[11]  Thomas M. Ludden,et al.  Estimation of Population Pharmacokinetic Parameters in the Presence of Non-compliance , 2003, Journal of Pharmacokinetics and Pharmacodynamics.

[12]  J. Wakefield,et al.  Modeling of Trough Plasma Bismuth Concentrations , 1997, Journal of Pharmacokinetics and Biopharmaceutics.

[13]  Sylvia Richardson,et al.  Markov Chain Monte Carlo in Practice , 1997 .

[14]  David J. Lunn,et al.  Markov Chain Monte Carlo Techniques for Studying Interoccasion and Intersubject Variability: Application to Pharmacokinetic Data , 1997 .

[15]  David B. Dunson,et al.  Bayesian Data Analysis , 2010 .

[16]  Peter Green,et al.  Markov chain Monte Carlo in Practice , 1996 .